- Research works
- 36 ▲ 174% vs 2018-21
- Citations
- 832 23.0 per fractional work
- Top-10% rate
- 15.6% all institutions 10.0%
- Open access
- 76% world 40%
- International
- 22% world 18%
Not ranked overall: VenatoRx Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does VenatoRx Pharmaceuticals (United States) work in?
In all years, 56% of research at VenatoRx Pharmaceuticals (United States) is in Life Sciences, 37% in Health Sciences. Its largest fields are Medicine (37%), Biochemistry, Genetics and Molecular Biology (33%), Immunology and Microbiology (11%). It does 2.7× the world's share of Life Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 4 domains and 11 fields, with their numbers
- Life Sciences2055.7%
- Health Sciences1336.6%
- Medicine1336.6%
- Physical Sciences37.1%
- Environmental Science13.7%
- Chemistry13.0%
- Materials Science00.4%
- Social Sciences00.6%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.1×. Every wedge is a field page.
All 7 fields, with their numbers
- Immunology and Microbiology9.05×2 works
- Biochemistry, Genetics and Molecular Biology6.85×7 works
- Medicine2.31×8 works
- Chemistry2.05×1 works
- Agricultural and Biological Sciences0.64×0 works
- Environmental Science0.56×0 works
- Materials Science0.23×0 works
Who are the top researchers at VenatoRx Pharmaceuticals (United States)?
Ranked on the quality score, Daniel C. Pevear, David A. Six and Denis M. Daigle lead among researchers whose main affiliation is VenatoRx Pharmaceuticals (United States).
- 1
Daniel C. Pevear
United States · #254,805 worldwide 5.3k citations · 82 works
- 2
David A. Six
United States · #703,617 worldwide 5.1k citations · 61 works
- 3
Denis M. Daigle
United States · #1,036,556 worldwide 1.9k citations · 36 works
- 4
Greg Moeck
United States · #1,312,038 worldwide 4k citations · 103 works
- 5
Cullen L. Myers
United States · #1,546,768 worldwide 499 citations · 15 works
- 6
Carlos Fernando de Oliveira
United States · #2,668,999 worldwide 437 citations · 16 works
- 7
Brittany Miller
United States · #2,884,088 worldwide 35 citations · 17 works
- 8
Allison L. Zulli
United States · #3,011,097 worldwide 587 citations · 26 works
- 9
Luigi Xerri
United States · #3,168,717 worldwide 861 citations · 46 works
Which keywords describe research at VenatoRx Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Antibiotic Resistance, Antimicrobial Resistance, ESKAPE Pathogens, Multidrug-Resistant Bacteria, Antibiotic Pharmacokinetics, Critically Ill Patients, Epidemiology and Drug Resistance.
- Hepatocellular Carcinoma
- Cell Signaling
- Resistance Genes
- Genomics
- Crystal Structure
- Antibiotics
- Microbial Communities
- Synaptic Plasticity
- Global Health
- Public Health
- Drug Resistance
- Antibiotic Pharmacokinetics
- Multidrug-Resistant Bacteria
- Antimicrobial Resistance
- Antibiotic Resistance
- ESKAPE Pathogens
- Epidemiology
- Critically Ill Patients
- Infectious Diseases
- Antimicrobial Stewardship
- Neurotransmission
- Immune Response
- Environmental Impact
- Antiviral Therapy
- Drug Discovery
- Liver Disease
- Signal Transduction
- Treatment
- Inflammation
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 29 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 29 words, with their numbers
- Antibiotic Resistance10▲ 66×7 topics
- Antimicrobial Resistance6▲ 69×3 topics
- ESKAPE Pathogens6▲ 319×1 topic
- Multidrug-Resistant Bacteria6▲ 319×1 topic
- Epidemiology5▲ 3.6×12 topics
- Antibiotic Pharmacokinetics5▲ 308×1 topic
- Critically Ill Patients5▲ 308×1 topic
- Drug Resistance3▲ 25×4 topics
- Infectious Diseases2▲ 27×2 topics
- Public Health2▲ 4.7×2 topics
- Antimicrobial Stewardship2▲ 207×1 topic
- Global Health2▲ 47×1 topic
- Neurotransmission2▲ 45×1 topic
- Synaptic Plasticity2▲ 19×1 topic
- Immune Response2▲ 7.4×4 topics
- Microbial Communities2▲ 12×2 topics
- Environmental Impact1▲ 3.0×2 topics
- Antibiotics1▲ 47×1 topic
- Antiviral Therapy1▲ 24×2 topics
- Crystal Structure1▲ 14×2 topics
- Drug Discovery1▲ 9.0×3 topics
- Genomics1▲ 9.9×4 topics
- Liver Disease1▲ 27×2 topics
- Resistance Genes1▲ 96×1 topic
- Signal Transduction1▲ 14×2 topics
- Cell Signaling1▲ 8.7×2 topics
- Treatment1▲ 2.4×5 topics
- Hepatocellular Carcinoma1▲ 13×2 topics
- Inflammation1▲ 1.21×7 topics
Which research topics does VenatoRx Pharmaceuticals (United States) publish most on?
By volume in 2022-now: Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Use and Resistance and Urinary Tract Infections Management.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Antibiotic Resistance in Bacteria Molecular Medicine 4 works
- 2 Antibiotics Pharmacokinetics and Efficacy Pharmacology 4 works
- 3 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 1 works
- 4 Urinary Tract Infections Management Epidemiology 1 works
- 5 Pharmaceutical and Antibiotic Environmental Impacts Pollution 0 works
- 6 Pneumonia and Respiratory Infections Epidemiology 0 works
- 7 Plant Pathogenic Bacteria Studies Plant Science 0 works
- 8 Infections and bacterial resistance Endocrinology 0 works
- 9 Bacterial Genetics and Biotechnology Genetics 0 works
- 10 Pharmacological Effects and Toxicity Studies Pediatrics, Perinatology and Child Health 0 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has VenatoRx Pharmaceuticals (United States)'s research output changed?
Output in 2022-2025 was 174% higher than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is VenatoRx Pharmaceuticals (United States) as a percentage of every work published that year, 0.000020% in 2024.
Fractional works of VenatoRx Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Malvern
- Siemens Healthcare (United States)
- Endo Pharmaceuticals (United States)
- Immaculata University
- Ricoh (United States)
- Reaction Biology Corporation (United States)
- Applied Pulsed Power (United States)
- TetraLogic Pharmaceuticals (United States)
- Saint-Gobain (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about VenatoRx Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.